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Background: Although human cancers have heterogeneous combinations of altered oncogenes, some crucial
genes are universally dysregulated in most cancers. One such gene, FEAT (faint expression in normal tissues,
aberrant overexpression in tumors), is uniformly overexpressed in a variety of human cancers and plays an
important role in tumorigenesis by suppressing apoptosis. However, the precise molecular mechanism through
which FEAT is upregulated during tumorigenesis remains largely unknown.
Methods: In this study, we used bioinformatic analyses to search for miRNAs that potentially target FEAT. We examined
the expression of FEAT protein level by western blotting and miR-16 level by qRT-PCR assay. Cancer cell lines (A549, MCF-7
and Huh-7) with miR-16 upregulation and FEAT silencing were established and the effects on apoptosis of cancer cells
in vitro were assessed. Luciferase reporter assay was also performed to investigate the interaction between miR-16 and FEAT.
Results:We identified a specific target site for miR-16 in the 3′-untranslated region (3′-UTR) of FEAT. Consistent with
the bioinformatic analyses, we identified an inverse correlation between the miR-16 and FEAT protein levels in
lung cancer, breast cancer, and hepatocellular cancer tissues. We then experimentally validated miR-16 as a direct
regulator of FEAT using cell transfection and luciferase assays. Finally, we demonstrated that the repression of FEAT
by miR-16 promoted the apoptosis of cancer cells.
Conclusions: Our findings provide the first clues regarding the role of miR-16 as a tumor suppressor in cancer cells
through the inhibition of FEAT translation.
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Although our understanding of the molecular mecha-
nisms of carcinogenesis has greatly improved, this know-
ledge has not led to the identification and development
of effective tools for cancer screening and prevention. In
theory, one of the most feasible and promising approaches
for cancer screening and prevention is targeting a com-
mon oncogene that occurs in most tumors. However, the
marked heterogeneity and complexity of human tumors
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unless otherwise stated.[1, 2]. Oncogenes that contribute to the development of
human cancers are highly variable among different types
of cancer and among individual tumors of the same type
[1, 2]. Thus, it is still poorly understood whether there are
crucial oncogenes that are commonly altered in diverse
cancers. Recently, Takahashi et al. investigated a previously
unrecognized protein, FEAT (faint expression in normal
tissues, aberrant overexpression in tumors), and identified
it as a novel, prominent promoter of tumorigenesis [3].
FEAT protein is encoded by METTL13 gene (methyltrans-
ferase like 13), and it is aberrantly overexpressed in most
human cancers but weakly expressed in normal tissues [3].
Remarkably, transgenic mice that ectopically expressed
FEAT spontaneously developed tumors, indicating that the
FEAT protein potently drives tumorigenesis in vivo [3].
Gene expression profiling has suggested that FEAT drives
receptor tyrosine kinase and hedgehog signaling pathwayshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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standing of the important roles of FEAT in cancer progres-
sion, the precise molecular mechanism through which FEAT
is upregulated during tumorigenesis remains largely un-
known. Further studies are needed to fully elucidate the regu-
lation of FEAT expression in normal and neoplastic tissues.
microRNAs (miRNAs) are a class of endogenously
expressed, small non-coding RNAs that play an import-
ant role in the regulation of gene expression at the post-
transcriptional level [4–6]. Some of these miRNAs have
attracted special attention for their involvement in the
initiation, progression, and metastasis of human cancers
[7, 8]. One particularly well-studied example is the ubi-
quitously expressed and highly conserved miR-16, one of
the first miRNAs that was known to be linked to human
malignancies [9]. Evidence indicates that miR-16 can
modulate the cell cycle, inhibit cell proliferation, promote
cell apoptosis, and suppress tumorigenicity both in vitro
and in vivo [10]. These effects can be explained by several
targets of miR-16: the anti-apoptotic gene B-cell lymph-
oma 2 (Bcl-2) [11]; numerous genes involved in the G1-S
transition such as CCND1 (cyclin D1), CCND3 (cyclin
D3), CCNE1 (cyclin E1), and CDK6 (cyclin-dependent kin-
ase 6) [12–14]; and genes involved in the Wnt signaling
pathway, such as WNT3A (wingless-type MMTV integra-
tion site family, member 3A) [14]. Consistently, miR-16 is
frequently deleted and/or downregulated in many types of
cancer, including chronic lymphocytic leukemia [9, 15],
prostate cancer [14], and lung cancer [16]. Thus, miR-16
is generally thought to be a key tumor-suppressive miRNA
that can target numerous oncogenes in various human
cancers.
Although the dysregulation of miR-16 and FEAT plays an
important role in carcinogenesis, no correlation between
FEAT and miR-16 in cancers has been reported. In this
study, we hypothesized that FEAT is a target of miR-16.
After measuring the expression levels of miR-16 and FEAT
in different types of human cancer tissues and paired non-
cancerous tissues, we detected an inverse correlation be-
tween miR-16 and FEAT in human cancers. Furthermore,
in this study, we experimentally investigated the direct
regulation of FEAT by miR-16 and the biological role of
miR-16 targeting FEAT in human cancer cells.
Methods
Cells and human tissues
The human lung cancer cell lines A549, human breast cancer
cell lines MCF-7, and human liver cancer cell lines Huh-7
were purchased from the Shanghai Institute of Cell Biology,
Chinese Academy of Sciences (Shanghai, China). A549,
MCF-7, and Huh-7 cells were cultured in DMEM supple-
mented with 10 % fetal bovine serum (GIBCO, CA, USA).
All cells were incubated in a 5 % CO2 at 37 °C in a water-
saturated atmosphere. The tumors and paired normaladjacent tissues were derived from patients undergoing a
surgical procedure at the Affiliated Gulou Hospital of
Nanjing University (Nanjing, China). All of the patients
or their guardians provided written consent, and the Ethics
Committee from Nanjing University approved all aspects
of this study. Tissue fragments were immediately frozen in
liquid nitrogen at the time of surgery and stored at −80 °C.
The clinical features of the patients are listed in Table 1.
RNA isolation and quantitative RT-PCR
Total RNA was extracted from the cultured cells and human
tissues using TRIzol Reagent (Invitrogen, Carlsbad, CA) ac-
cording to the manufacturer’s instructions. Assays to quan-
tify miRNAs were performed using Taqman miRNA probes
(Applied Biosystems, Foster City, CA) according to the
manufacturer’s instructions. Briefly, 1 μg of total RNA was
reverse-transcribed to cDNA using AMV reverse transcript-
ase (TaKaRa, Dalian, China) and a stem-loop RT primer
(Applied Biosystems). The reaction conditions were as
follows: 16 °C for 30 min, 42 °C for 30 min, and 85 °C for
5 min. Real-time PCR was performed using a TaqMan PCR
kit on an Applied Biosystems 7300 Sequence Detection Sys-
tem (Applied Biosystems). The reactions were incubated in a
96-well optical plate at 95 °C for 10 min, followed by 40 cy-
cles of 95 °C for 15 s and 60 °C for 1 min. All of the reactions
were run in triplicate. After the reaction, the cycle threshold
(CT) data were determined using fixed threshold settings,
and the mean CT of the triplicate PCRs was determined. A
comparative CT method was used to compare each condi-
tion with the controls. The relative levels of the miRNAs in
the cells and tissues were normalized to U6. The amount of
miRNA relative to the internal control U6 was calculated
using the 2-△△CT equation, in which △△CT= (CT miRNA -
CT U6)target—(CT miRNA—CT U6)control. To quantify the FEAT
mRNA, 1 μg of total RNA was reverse-transcribed to cDNA
using oligo(dT) and Thermoscript (TaKaRa) in the reaction,
which was performed under the following conditions: 42 °C
for 60 min and 70 °C for 10 min. Next, real-time PCR was
performed using the RT product, SYBER Green Dye
(Invitrogen) and specific primers for FEAT and GAPDH.





reactions were incubated at 95 °C for 5 min, followed by
40 cycles of 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s.
After the reactions were complete, the CT values were deter-
mined by setting a fixed threshold. The relative amount of
FEAT mRNA was normalized to GAPDH.
Overexpression and knockdown of miR-16
Synthetic pre-mir-16, anti-mir-16, and scrambled negative
control RNAs were purchased from Ambion (Austin, TX,
Table 1 Clinical Features of cancer patients
Cancer type Tumor subtype Pathological stage
Lung cancer #1 Adenocarcinoma IIIA
Lung cancer #2 Adenocarcinoma IIB
Lung cancer #3 Squamous cell carcinoma IIIA
Breast cancer #1 Invasive Ductal Carcinoma III
Breast cancer #2 Invasive Ductal Carcinoma III
Breast cancer #3 Invasive Ductal Carcinoma II
Hepatocellular cancer #1 Hepatocellular carcinoma II
Hepatocellular cancer #2 Hepatocellular carcinoma II
Hepatocellular cancer #3 Hepatocellular carcinoma III
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dishes, and the cells were transfected with Lipofectamine
2000 (Invitrogen) on the following day, when the cells were
approximately 70 % confluent. In each well, equal amounts
of pre-mir-16, anti-mir-16, or scrambled negative control
RNA were used. The cells were harvested 24 h after
transfection for quantitative RT-PCR and Western blotting.
Luciferase reporter assay
To test the direct binding of miR-16 to the target gene
FEAT, a luciferase reporter assay was performed as pre-
viously described [17]. The entire 3′-untranslated region
(3′-UTR) of human FEAT was amplified using PCR with
human genomic DNA as a template. The PCR products
were inserted into the p-MIR-reporter plasmid (Ambion),
and the insertion was confirmed to be correct via sequen-
cing. To test the binding specificity, the sequences that
interacted with the miR-16 seed sequence were mutated
(from UGCUGCU to ACGACGA), and the mutant FEAT
3′-UTR was inserted into an equivalent luciferase re-
porter. For luciferase reporter assays, A549, MCF-7, and
Huh-7 cells were cultured in 24-well plates, and each well
was transfected with 1 μg of firefly luciferase reporter
plasmid, 1 μg of a β-galactosidase (β-gal) expression plas-
mid (Ambion), and equal amounts (100 pmol) of pre-mir-
16, anti-mir-16, or the scrambled negative control RNA
using Lipofectamine 2000 (Invitrogen). The β-gal plasmid
was used as a transfection control. Twenty-four hours
post-transfection, the cells were assayed using a luciferase
assay kit (Promega, Madison, WI, USA).
Plasmid construction and siRNA interference assay
An siRNA sequence targeting the human FEAT cDNA
was purchased from Santa Cruz (sc-88139, Santa Cruz
Biotechnology, CA, USA). A scrambled siRNA was in-
cluded as a negative control. A mammalian expression
plasmid encoding the human FEAT open reading frame
(pReceiver-M02-FEAT) was purchased from GeneCopoeia
(Germantown, MD, USA). An empty plasmid served as a
negative control. The FEAT expression plasmid and FEATsiRNA were transfected into A549 cells using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instruc-
tions. Both total RNA and protein were isolated 24 h post-
transfection. The FEAT mRNA and protein expression levels
were assessed by quantitative RT-PCR and Western blotting.
Protein extraction and western blotting
All cells were rinsed with PBS (pH 7.4) and lysed in RIPA
Lysis buffer (Beyotime, China) supplemented with a Protease
and Phosphatase Inhibitor Cocktail (Thermo Scientific
78440) on ice for 30 min. The tissue samples were frozen
solid with liquid nitrogen, ground into a powder and lysed in
RIPA Lysis buffer containing the Protease and Phosphatase
Inhibitor Cocktail on ice for 30 min. When necessary, sonic-
ation was used to facilitate lysis. Cell lysates or tissue homog-
enates were centrifuged for 10 min (12000 g, 4 °C). The
supernatant was collected, and the protein concentration
was calculated using a Pierce BCA protein assay kit (Thermo
Scientific, Rockford, IL, USA). The protein levels were ana-
lyzed using Western blots with the corresponding antibodies.
The protein levels were normalized by probing the same
blots with a GAPDH antibody. The antibodies were
purchased from the following sources: anti-FEAT (X-20)
(sc-101995, Santa Cruz Biotechnology, CA, USA) and anti-
GAPDH (sc-365062, Santa Cruz Biotechnology, CA, USA).
Protein bands were analyzed using the ImageJ software.
Apoptosis assays
The apoptosis of A549 cells was tested using an Annexin
V-FITC/propidium iodide (PI) staining assay. A549 cells
were cultured in 12-well plates and transfected with pre-
mir-16, anti-mir-16, FEAT siRNA, or the FEAT overex-
pression plasmid to induce apoptosis. Pre-mir-control,
anti-mir-control, control siRNA, and control plasmid
served as negative controls. Cells were cultured over-
night with both serum-containing complete medium and
serum-depleted medium; and the attached and floating
cells were then harvested. Flow cytometry analysis of apop-
totic cells was performed using an Annexin V-FITC/PI
staining kit (BD Biosciences, CA, USA). After washes with
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(100 mM HEPES, pH 7.4, 100 mM NaCl, and 25 mM
CaCl2), followed by staining with Annexin V-FITC/PI at
room temperature in darkness for 15 min. Apoptotic cells
were then evaluated by gating PI and Annexin V-positive
cells on a fluorescence-activated cell-sorting (FACS) flow
cytometer (BD Biosciences, San Jose, CA). All experiments
were performed in triplicate.
Functional annotation
Based on miRTarBase, there are now more than 100 ex-
perimental validated target genes of miR-16 [18]. the Gene
Ontology (GO) classification was performed to gain in-
sights into the biological functions of miR-16 target genes,
and the Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway enrichment analysis was performed to
detect the potential pathway of miRNA target genes.
KEGG pathway database is a recognized and comprehen-
sive database including all kinds of biochemistry pathways
[19]. The online based software GENECODIS was utilized
in those functional annotation [20].
Statistical analysis
All of the Western blotting images are representative of at
least three independent experiments. Quantitative RT-PCR,
the luciferase reporter assay, and the cell viability and
apoptosis assays were performed in triplicate, and each ex-
periment was repeated several times. The data shown are
the mean ± SE of at least three independent experiments.
The differences were considered statistically significant at
p < 0.05 using Student’s t-test.
Results
Upregulation of FEAT protein in human cancer tissues
We first determined the expression patterns of FEAT in
lung cancer, breast cancer, and hepatocellular cancer tis-
sues. After measuring the protein levels of FEAT in these
cancer tissues and the corresponding noncancerous
tissues, we found that FEAT protein is dramatically over-
expressed in cancer tissues but totally absent in normal
tissues (Fig. 1a). However, FEAT mRNA was readily de-
tected in noncancerous tissues, and its levels were slightly
upregulated in cancer tissues (Fig. 1b). This disparity
between protein and mRNA in FEAT expression in
cancers strongly suggests that a post-transcriptional
mechanism is involved in FEAT regulation.
Identification of conserved miR-16 target sites within the
3′-UTR of FEAT
One important mode of post-transcriptional regulation
is the repression of mRNA transcripts by miRNAs. miRNAs
are therefore likely to play a biologically relevant role in
regulating FEAT expression in cancer. Three computa-
tional algorithms, including TargetScan [21], miRanda[22], and PicTar [23], were used in combination to iden-
tify potential miRNAs that can target FEAT. Using these
approaches, miR-16 was identified as a candidate regula-
tory miRNA of FEAT. The predicted interaction between
miR-16 and the target sites in the FEAT 3′-UTR are illus-
trated in Fig. 1c. One potential miR-16 target site was
found in the 3′-UTR of the FEAT mRNA sequence. The
minimum free energy value of this hybrid is −22.0 kcal/mol,
which is well within the range of genuine miRNA-target
pairs. Moreover, perfect base pairing occurs between the
seed region (the core sequence that encompasses the first
2–8 bases of the mature miRNA) and the cognate targets.
Furthermore, the miR-16 binding sequence in the FEAT
3′-UTR is highly conserved across species.
Detection of an inverse correlation between the miR-16
and FEAT levels in cancer tissues
miRNAs are generally thought to have expression patterns
that are the opposite of those of their targets [4–6]. We
next investigated whether miR-16 was inversely correlated
with FEAT in cancer tissues. After determining the levels
of miR-16 in the same three pairs of lung cancer, breast
cancer, and hepatocellular cancer tissues and the corre-
sponding noncancerous tissues, we showed that the miR-16
levels were consistently downregulated in cancer tissues
(Fig. 1d). Combining the computational prediction with
the detection of inverse correlation between miR-16 and
FEAT in vivo, it is quite likely that miR-16 is involved in
the post-transcriptional regulation of FEAT.
Validation of FEAT as a direct target of miR-16
The correlation between miR-16 and FEAT was further
examined by evaluating FEAT expression in human lung
adenocarcinoma A549 cells, human breast adenocarcinoma
MCF-7 cells, and human hepatocellular carcinoma Huh-7
cells after overexpressing or knocking down miR-16. In
these experiments, miR-16 overexpression was achieved by
transfecting the cells with pre-mir-16 (a synthetic RNA
oligonucleotide duplex mimicking the miR-16 precursor),
and miR-16 knockdown was achieved by transfecting the
cells with anti-mir-16 (a chemically modified antisense
oligonucleotide designed to specifically target mature
miR-16). As anticipated, the miR-16 levels were sig-
nificantly increased in A549, MCF-7, and Huh-7 cells
when these cells were transfected with pre-mir-16, whereas
the miR-16 levels were decreased when these cells were
transfected with anti-mir-16 (Fig. 2a). The expression of
the FEAT protein was reduced by the overexpression of
miR-16 and increased by the knockdown of miR-16 in
A549, MCF-7, and Huh-7 cells (Fig. 2, b and c). To deter-
mine the level at which miR-16 influenced FEAT expres-
sion, we repeated the above-mentioned experiments and
examined the expression of FEAT mRNA after transfec-
tion. Although the intracellular level of miR-16 was
Fig. 1 Expression levels of the FEAT protein, FEAT mRNA, and miR-16 in cancer tissues. a Western blotting analysis of the expression levels of the
FEAT protein in three pairs of lung (LCT), breast (BCT), and hepatocellular cancer tissues (HCT) and in normal adjacent tissues (NAT). b Quantitative
RT-PCR analysis of the relative expression levels of FEAT mRNA in three pairs of lung, breast, and hepatocellular cancer tissues and in normal adjacent
tissues. c Schematic description of the hypothetical duplexes formed by the interactions between the binding site in the FEAT 3′-UTR (top) and miR-16
(bottom). The predicted free energy value of the hybrid is indicated. The seed recognition site is denoted, and all nucleotides in this region are highly
conserved across species. (D) Quantitative RT-PCR analysis of the expression levels of miR-16 (in the form of the miRNA/U6 ratio) in three pairs of lung,
breast, and hepatocellular cancer tissues and in normal adjacent tissues. **, P< 0.01; ***, P< 0.001
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and anti-mir-16, the alteration of the miR-16 levels did not
affect the FEAT mRNA levels (Fig. 2d). These results dem-
onstrate that miR-16 specifically regulates FEAT protein
expression at the post-transcriptional level, which is a typ-
ical miRNA-mediated regulation mechanism.
To determine whether the negative regulatory effects
that miR-16 exerted on FEAT expression were mediated
through the binding of miR-16 to the presumed sites in
the 3′-UTR of the FEAT mRNA, the full-length FEAT
3′-UTR that contained the sole presumed miR-16 binding
site was fused downstream of the firefly luciferase gene in
a reporter plasmid. The resulting plasmid was transfected
into A549, MCF-7, and Huh-7 cells along with pre-mir-16
or anti-mir-16. As expected, the overexpression of miR-16
resulted in a significant reduction of luciferase reporter
activity compared with transfection with pre-scramble
control, whereas the inhibition of miR-16 resulted in
an increase in reporter activity compared with transfec-
tion with anti-scramble control (Fig. 2e). Furthermore, weintroduced point mutations into the corresponding com-
plementary sites in the FEAT 3′-UTR to eliminate the
predicted miR-16 binding site. This mutated luciferase re-
porter was unaffected by both the overexpression and
knockdown of miR-16 (Fig. 2e). This finding suggests that
the binding site strongly contributes to the interaction
between miR-16 and FEAT mRNA. In conclusion, our
results demonstrate that miR-16 directly recognizes and
binds to the 3′-UTR of the FEAT mRNA transcript
thereby inhibiting FEAT translation.
miR-16 promotes the apoptosis of cancer cells by
regulating FEAT
We next focused on studying the role of miR-16 in regu-
lating FEAT. Because FEAT is known to be involved in
cell apoptosis regulation [3], we investigated whether the
overexpression or knockdown of miR-16 or FEAT would
impact cell apoptosis in A549 cells using flow cytometry
analysis. The efficient overexpression or knockdown of
FEAT is shown in Fig. 3, a-c. In support of the notion
Fig. 2 Direct regulation of FEAT expression by miR-16 at the posttranscriptional level. a Quantitative RT-PCR analysis of the miR-16 levels in A549,
MCF-7, and Huh-7 cells transfected with pre-mir-control, pre-mir-16, anti-mir-control, and anti-mir-16. b and c Western blot analysis of the FEAT
protein levels in A549, MCF-7, and Huh-7 cells transfected with pre-mir-control, pre-mir-16, anti-mir-control, and anti-mir-16. B: representative
image; C: quantitative analysis. d Quantitative RT-PCR analysis of FEAT mRNA levels in A549, MCF-7, and Huh-7 cells transfected with pre-mir-control,
pre-mir-16, anti-mir-control, and anti-mir-16. e Firefly luciferase reporters containing wild-type (WT) or mutant (MUT) miR-16 binding sites in the FEAT
3′-UTR were co-transfected into A549, MCF-7, and Huh-7 cells with pre-mir-control, pre-mir-16, anti-mir-control, and anti-mir-16. Twenty-four hours
post-transfection, the cells were assayed using a luciferase assay kit. ***, P < 0.001
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cells transfected with FEAT siRNA showed a promotion
of cell apoptosis (Fig. 3, d and e). In contrast, transfec-
tion with the FEAT-overexpressing plasmid, which spe-
cially expresses the full-length open reading frame (ORF)
of FEAT without the miR-16–responsive 3′-UTR, had an
opposite effect on cell apoptosis (Fig. 3, d and e). Subse-
quently, we assessed the role of miR-16 in cell apoptosis.
As expected, A549 cells transfected with pre-mir-16 ex-
hibited a significantly higher rate of cell apoptosis, whereas
A549 cells transfected with anti-mir-16 had a lower apop-
tosis rate (Fig. 3, d and e). Moreover, compared with cells
that had been transfected with pre-mir-16, those trans-
fected with pre-mir-16 and the FEAT-overexpressing plas-
mid exhibited significantly lower apoptosis rates (Fig. 3, d
and e), suggesting that miR-16-resistant FEAT is sufficient
to rescue the suppression of FEAT by miR-16 and attenu-
ate the pro-apoptotic effect of miR-16 on cancer cells.
Taken together, the results indicate that miR-16 can pro-
mote cell apoptosis by silencing FEAT.Discussion
The significance of overexpressed proteins in cancer is
recognized as a potential lead for a variety of diagnostic and
therapeutic approaches for cancers. Studies that identify
and characterize common oncogenic proteins will hopefully
advance molecular-targeted cancer screening and preven-
tion. However, due to the marked heterogeneity and com-
plexity of different types of human cancers, it is rather
difficult to identify such proteins that are commonly altered
in diverse cancers. Notably, a previously unrecognized pro-
tein, FEAT, was recently found to be highly expressed in
an unusually wide range of tumors but not expressed in
most normal tissues [3], suggesting that FEAT is a ubiqui-
tous protein that is involved in human cancer. FEAT was
originally purified from rat livers as a protein that inhibits
nuclear apoptosis in vitro [3]. Ex vivo experiments con-
firmed that FEATattenuates apoptotic cell death [3]. Stud-
ies have demonstrated that FEAT is highly oncogenic
in vivo [3]. However, despite these recent advances in our
understanding of the important roles of FEAT in cancer
Fig. 3 The role of miR-16 targeting FEAT in the regulation of apoptosis of cancer cells. a Quantitative RT-PCR analysis of FEAT mRNA levels in
A549 cells treated with control siRNA, FEAT siRNA, control plasmid, and FEAT plasmid. b and c Western blot analysis of FEAT protein levels in
A549 cells treated with control siRNA, FEAT siRNA, control plasmid, and FEAT plasmid. B: representative image; C: quantitative analysis. (D and E)
A549 cells were transfected with equal doses of pre-mir-control, pre-mir-16, anti-mir-control, anti-mir-16, control siRNA, FEAT siRNA, control plasmid,
FEAT plasmid, or with pre-mir-control plus control plasmid, pre-mir-16 plus control plasmid, pre-mir-control plus FEAT plasmid, or pre-mir-16 plus FEAT
plasmid. Cell apoptosis profiles were analyzed by flow cytometry. The biparametric histogram shows cells in early (bottom right quadrant) and
late apoptotic states (upper right quadrant). Viable cells are double negative (bottom left quadrant). d: representative image; e: quantitative
analysis. ***, P < 0.001
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which FEAT is upregulated during tumorigenesis remains
largely unknown. In this study, we showed that silencing
FEAT expression using siRNA could promote cell apop-
tosis in cancer cells, whereas overexpressing FEAT had
an opposite effect, validating its role as an essential
oncogenic protein during tumorigenesis. Interestingly, we
identified discordance between the FEAT protein and
mRNA levels in human lung cancer, breast cancer, and he-
patocellular cancer tissues. The results suggest that a
post-transcriptional regulation mechanism is involved in
FEAT repression. One centrally important mode of post-
transcriptional regulation is the repression of mRNAtranscripts by miRNAs. Therefore, we searched for miR-
NAs that could target FEAT and experimentally vali-
dated miR-16 as a direct regulator of FEAT. The results
identified miR-16 as a novel link between the FEAT regu-
latory pathway and the pathogenesis of cancer. Consider-
ing that miR-16 is highly expressed in normal tissues and
frequently deleted and downregulated in many types of
cancer tissues, the results also explain, at least in part,
why FEAT is aberrantly overexpressed in most human
cancers but weakly expressed in normal tissues.
In this study, we further investigated whether the cel-
lular phenotypes especially cell apoptosis were regulated
by miR-16 targeting FEAT. We showed that miR-16
Liang et al. BMC Cancer  (2015) 15:448 Page 8 of 9could suppress FEAT expression and, in turn, promote
apoptosis in cancer cells. The results reveal a critical role
for miR-16 as a tumor suppressor and pro-apoptotic mol-
ecule in carcinogenesis through the repression of FEAT
translation. In fact, miR-16 has been reported to act as a
tumor-suppressive miRNA in many cancer types [9–16],
and multiple apoptosis-related genes are targeted by miR-16,
including BCL-2, CCND1, CCND3, and CCNE1 [9, 13].
We performed KEGG pathway analysis and GO annota-
tion analysis on the experimental validated target genes of
miR-16, and the results showed that most of these target
genes were indeed anti-apoptotic factors (Additional file 1
Table S1 and S2). An emerging common theme is that
multiple targets regulated by a single miRNA can act in
concert, rather than individually, to regulate the same bio-
logical process, such as apoptosis. The coordinated regula-
tion of many targets by a single miRNA may allow for a
prompt cellular response to the apoptosis signals. In this
study, it is noted that restoring FEAT expression can suc-
cessfully attenuate the pro-apoptotic effects of miR-16 on
cancer cells, although miR-16 has many other targets. The
results suggest that targeting FEAT is a major mechanism
by which miR-16 exerts its tumor-suppressive and pro-
apoptotic function. Therefore, the modulation of FEAT by
miR-16 might explain, at least in part, why the downregu-
lation of miR-16 during carcinogenesis can accelerate
cancer progression.
Taken together, this study delineates a novel regulatory
network employing miR-16 and FEAT to fine-tune cell
apoptosis in lung, breast, and hepatocellular cancer cells.
This study may provide a potential novel target for fu-
ture cancer therapy.Additional file
Additional file 1: miR-16 promotes the apoptosis of human cancer
cells by targeting FEAT.Competing interests
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